Gilteritinib for treating relapsed or refractory acute myeloid leukaemia – Final appraisal document
In DRAFT guidance, gilteritinib monotherapy is recommended as an option for treating relapsed or refractory FLT3-mutation-positive acute myeloid leukaemia in adults only if the company provides gilteritinib according to the commercial arrangement.
Source:
National Institute for Health and Care Excellence
SPS commentary:
The draft guidance states that it should not be given as maintenance therapy after a haematopoietic stem cell transplant. The appeal period for this appraisal will close on 30th July 2020 and final guidance is expected to be published in August 2020.